diglycolic acid monobenzyl ester | 154741-21-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diglycolic acid monobenzyl ester
• 英文别名: 2-(2-(benzyloxy)-2-oxoethoxy)acetic acid；2-{[Benzyloxycarbonyl]methoxy}acetic acid；Acetic acid, (carboxymethoxy)-, 1-(phenylmethyl) ester；2-(2-oxo-2-phenylmethoxyethoxy)acetic acid
• CAS: 154741-21-6
• 化学式: C₁₁H₁₂O₅
• 分子量: 224.213
• InChiKey: DYLIIGBRGWUCEP-UHFFFAOYSA-N

物化性质

• 沸点：
  412.3±25.0 °C(Predicted)
• 密度：
  1.272±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diglycolic acid monobenzyl ester 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 2.5h， 生成
  参考文献：
  名称：

  [EN] NEW BIS ESTERS OF IVY SAPOGENINS FOR RUMINANTS
  [FR] NOUVEAUX BIS-ESTERS DE SAPOGÉNINES DE LIERRE POUR RUMINANTS

  摘要：

  本发明涉及合成的藤黄皂苷双酯，以及它们在反刍动物中用于改善反刍动物生长性能、减少瘤胃甲烷排放、减少尿液氨排泄和/或减少瘤胃乙酸到丙酸比率的用途。此外，还涉及一种含有藤黄皂苷双酯的反刍动物饲料组合物，以及新型藤黄皂苷双酯。

  公开号：

  WO2016193309A1
• 作为产物：
  描述：

  二甘醇酐 、 苯甲醇 在 吡啶 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以5.08 g的产率得到diglycolic acid monobenzyl ester
  参考文献：
  名称：

  [EN] NEW BIS ESTERS OF IVY SAPOGENINS FOR RUMINANTS
  [FR] NOUVEAUX BIS-ESTERS DE SAPOGÉNINES DE LIERRE POUR RUMINANTS

  摘要：

  本发明涉及合成的藤黄皂苷双酯，以及它们在反刍动物中用于改善反刍动物生长性能、减少瘤胃甲烷排放、减少尿液氨排泄和/或减少瘤胃乙酸到丙酸比率的用途。此外，还涉及一种含有藤黄皂苷双酯的反刍动物饲料组合物，以及新型藤黄皂苷双酯。

  公开号：

  WO2016193309A1

文献信息

• Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
  申请人：——

  公开号：US20020143007A1

  公开（公告）日：2002-10-03

  The present invention describes novel nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one &agr;-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型硝化和/或硝基化α-肾上腺素受体拮抗剂，以及包含至少一种硝化和/或硝基化α-肾上腺素受体拮抗剂的新型组合物，以及可选地包含一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物的化合物，和/或一种或多种血管活性药物。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物，和/或一种或多种血管活性药物的新型组合物。本发明还提供了用于治疗或预防男性和女性的性功能障碍、增强男性和女性的性反应，以及治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、急迫性尿失禁或过度活跃膀胱，以及逆转麻醉状态的方法。
• AMINO ACID DERIVATIVES AND ABSORBABLE POLYMERS THEREFROM
  申请人：Bezwada Biomedical, LLC

  公开号：US20160257643A1

  公开（公告）日：2016-09-08

  The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.

  本发明涉及发现一类新的可水解氨基酸衍生物和可吸收聚酯酰胺、聚酰胺、聚环氧化物、聚脲和由此制备的聚氨酯。由此产生的可吸收聚合物可用于药物输送、组织工程、组织粘合剂、粘附防止、骨蜡配方、医疗器械涂层、支架、支架涂层、高度多孔泡沫、网状泡沫、伤口护理、心血管应用、骨科器械、表面改性剂和其他可植入医疗器械。此外，这些可吸收聚合物应具有受控的降解特性。
• AMINO ACID DERIVATIVES AND ABSORABLE POLYMERS THEREFROM
  申请人：Bezwada Rao S.

  公开号：US20120208896A1

  公开（公告）日：2012-08-16

  The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.

  本发明涉及一种新类水解性氨基酸衍生物和可吸收聚酯酰胺、聚酰胺、聚环氧化物、聚脲和由此制备的聚氨酯。所得的可吸收聚合物可用于药物输送、组织工程、组织粘合剂、粘附预防、骨蜡配方、医疗器械涂层、支架、支架涂层、高度多孔泡沫、网状泡沫、伤口护理、心血管应用、骨科器械、表面改性剂和其他可植入医疗器械。此外，这些可吸收聚合物应具有受控降解特性。
• Synthesis and GGCT Inhibitory Activity of <i>N</i>-Glutaryl-L-alanine Analogues
  作者：Hiromi Ii、Tatsuhiro Yoshiki、Naoyuki Hoshiya、Jun’ichi Uenishi

  DOI：10.1248/cpb.c16-00167

  日期：——

  cycle to release 5-oxoproline and amino acid. Eighteen N-acyl-L-alanine analogues including eleven new compounds have been synthesized and examined for their inhibitory activity against recombinant human GGCT protein. Simple N-glutaryl-L-alanine was found to be the most potent inhibitor for GGCT. Other N-glutaryl-L-alanine analogues having methyl and dimethyl substituents at the 2-position were moderately

  γ-谷氨酰环转移酶（GGCT）是一种重要的酶，可在γ-谷氨酰循环中裂解γ-谷氨酰氨基酸，从而释放出5-氧代脯氨酸和氨基酸。已合成了包括11种新化合物在内的18种N-酰基-L-丙氨酸类似物，并研究了其对重组人GGCT蛋白的抑制活性。发现简单的N-谷氨酰-L-丙氨酸是GGCT最有效的抑制剂。其他在2位具有甲基和二甲基取代基的N-戊二烯基-L-丙氨酸类似物是中等有效的，而N-（3R-氨基戊二烯基）-L-丙氨酸是在3-位具有（R）-氨基的底物。相反，在3-氮杂戊二烯基碳上具有N-甲基取代基的底物或N-（N-甲基-3-氮杂戊二烯基）-L-丙氨酸反过来表现出优异的抑制性能。
• Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds
  申请人：Garvey S. David

  公开号：US20050187222A1

  公开（公告）日：2005-08-25

  The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型的硝化和/或亚硝化α-肾上腺素受体拮抗剂，以及包含至少一种硝化和/或亚硝化α-肾上腺素受体拮抗剂的新型组合物，以及可选地，一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物的化合物和/或一种或多种血管活性剂。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的新型组合物。本发明还提供了用于治疗或预防男女性功能障碍、增强男女性反应、治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、切欲性尿失禁或膀胱过度活动，并逆转麻醉状态的方法。